Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population

Status unconfirmed

Conditions studied: Increased Drug Resistance

In brief

The primary objective of this prospective clinical registry is to determine the prevalence and level of thienopyridine resistance seen in a population undergoing contemporary percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG).

Key facts

Study ID

NCT01408927

Run by

Medstar Health Research Institute

People needed

1000

Starts

2008-10-01

Expected to finish

2016-01-01

Last updated by the study team

2014-08-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient >18 years old.
• PCI group only: Patient scheduled to undergo cardiac catheterization or underwent percutaneous coronary intervention (PCI), during hospital stay.
• CABG group only: Patient is scheduled to undergo, or has underwent, coronary artery bypass surgery with at least one saphenous vein graft.
• Treated with a loading dose of clopidogrel or prasugrel at least 6 hours prior to the blood draw, or on a maintenance dose of clopidogrel or prasugrel for a minimum of 5 days.
• Genetic testing subgroup only: Patient has undergone PCI (only), and has been treated with a thienopyridine as in 4.

You may not qualify if…

• Known allergies to aspirin, clopidogrel, or prasugrel;
• Use of a glycoprotein (GP) IIb/IIIa within 8 hours of the blood draw;
• Patient known to be pregnant or lactating;
• Patient with known history of bleeding diathesis or currently active bleeding;
• Platelet count <100,000/mm the day of the blood draw;
• Hematocrit <25% the day of the blood draw;
• On warfarin therapy at the time of the blood draw;
• Known blood transfusion within the preceding 10 days of the blood draw;
• Patient who has received NSAID (not including ASA) within preceding 24 hours of the blood draw;
• Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study.

Where it is running

• Washington Hospital Center — Washington D.C., District of Columbia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.